Guardant Health ((GH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The Shield Post-Approval Study Protocol by Guardant Health aims to assess the performance of the Shield blood test for colorectal cancer (CRC) screening in individuals aged 45 to 81 at average risk. This prospective, longitudinal study uses real-world evidence to validate the test’s efficacy, with colonoscopy as the reference standard.
Intervention/Treatment: The study tests the Shield Blood Test, a diagnostic tool designed for colorectal cancer screening, providing a non-invasive alternative to traditional methods.
Study Design: This observational cohort study follows a prospective time perspective, collecting blood samples with DNA for analysis. It focuses on enrolled subjects meeting specific criteria to evaluate the test’s effectiveness over time.
Study Timeline: The study began on March 11, 2025, with its latest update on July 18, 2025. These dates mark the study’s progression and ongoing data collection efforts.
Market Implications: Guardant Health’s ongoing study could influence its stock performance positively, as successful validation of the Shield test may enhance market confidence. This development is crucial amid competitive pressures in the diagnostic testing industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.